Genes copy number as a marker of low-invasive assessment of rectal tumors radiotherapy effectiveness.

Authors

null

Marina A. Gusareva

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

Marina A. Gusareva , Natalia G Kosheleva , Natalya B. Fatkina , Anna A. Solntseva , Lyudmila Ya. Rozenko , Aliya K. Donskaya , Ekaterina O. Vasilieva , Elena A. Karnauhova , Julia N. Krokhmal , Peter N. Gabrichidze , Vladimir A. Dontsov , Umar M. Gaziev , Vladislav M. Legostaev , Olga V. Shlyakhova , Natalia A. Lyman , Gennady V. Balitsky , V. A. Nosov , A. B. Kravchenko , Denis S. Kutilin

Organizations

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation, National Medical Research Oncology Center, Rostov-on-Don, Russian Federation

Research Funding

Other
Ministry of Health of the Russian Federation

Background: Radiotherapy (RT) is a key component of rectal cancer (RC) treatment, however, nonresponsiveness in patients to preoperative RT is very common, usually due to the tumor cells radioresistance, mediated by their molecular characteristics, such as gene expression. The features of mRNA rapid degradation in extracellular environment make this indicator unsuitable for low invasive diagnostics. The solution to this problem is possible by switching to a more stable marker - the copy number variation (CNV), which can be determined in the extracellular DNA (cfDNA) circulating in the blood plasma. Therefore, the aim of the study was to identify the relationship between the level of genes CNV in the cfDNA of blood plasma with the effectiveness of rectal tumors RT. Methods: We used cfDNA preparations from blood plasma obtained before RT from 200 patients with RC, as well as from blood plasma of 50 apparently healthy donors (AHD, without cancer). RT was carried out on a linear accelerator Novalis TX (SFD = 2.4 Gy, TFD = 54.0 Gy). Blood samples were separated into plasma and cell fraction by centrifugation. Isolation of cfDNA from blood plasma was performed using the phenol-chloroform method. Determination CNV of 5 genes (BRCA2, H2AX, CASP9, RBBP8 and BCL2) was performed using Real-Time qPCR method. Differences were assessed using Mann-Whitney test; the Bonferroni correction was used to correct multiple comparisons. Results: RT results for 200 patients allowed them to be divided into 2 groups. After RT, 120 patients showed complete tumor regression (group 1), 50 patients showed insignificant tumor regression and 30 patients did not regress (group 2). In cfDNA of group 1 patients was found CNV decrease (p < 0.05) of H2AX and RBBP8 genes by 2.5 and 2.0 times, respectively, relative to AHD group. In the cfDNA of group 2patients an increase (p < 0.05) of BRCA2, H2AX, RBBP8 and BCL2 genes CNV was found by 2.0, 2.2, 2.0 and 2.0 times, respectively, relative to AHD group. Only 2 genes CNV differed in group 1 from group 2: the CNV of H2AX and RBBP8 was 5.4 and 4.0 times less respectively (p < 0.005). Conclusions: Thus, it has been found that increased CNV of genes BRCA2, H2AX, BCL2, RBBP8 in blood plasma cfDNA is associated with low efficiency of RT. At the same time, the CNV of H2AX and RBBP8 genes in cfDNA of patients with RC has the greatest potential as a marker of the RT effectiveness.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3025)

DOI

10.1200/JCO.2021.39.15_suppl.3025

Abstract #

3025

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Natalia G Kosheleva

First Author: Denis S. Kutilin

Abstract

2020 ASCO Virtual Scientific Program

The genes CNV and expression as a factors of HT-29 cells radioresistance.

First Author: Natalia G Kosheleva

Abstract

2022 ASCO Annual Meeting

Competing endogenous RNA network features and prostate tumor cell sensitivity to radiotherapy.

First Author: Denis S. Kutilin